| pubmed-article:15118525 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15118525 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15118525 | lifeskim:mentions | umls-concept:C1719672 | lld:lifeskim |
| pubmed-article:15118525 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:15118525 | lifeskim:mentions | umls-concept:C1170000 | lld:lifeskim |
| pubmed-article:15118525 | lifeskim:mentions | umls-concept:C0380964 | lld:lifeskim |
| pubmed-article:15118525 | lifeskim:mentions | umls-concept:C1882417 | lld:lifeskim |
| pubmed-article:15118525 | pubmed:issue | 5 Suppl | lld:pubmed |
| pubmed-article:15118525 | pubmed:dateCreated | 2004-4-30 | lld:pubmed |
| pubmed-article:15118525 | pubmed:abstractText | Coagulation activation is part of the acute innate host response to infection that, when uncontrolled, may contribute to organ dysfunction and death. Activated protein C limits excessive coagulation activation by inactivating factors Va and VIIIa. The factor V Leiden mutation (R506Q), a prothrombotic gene polymorphism, disrupts the activity of this natural anticoagulant by rendering factor Va partially resistant to inactivation by activated protein C. Previous findings in the mouse factor V Leiden endotoxemia model and in patients with severe sepsis suggest that factor V Leiden constitutes a rare example of a balanced gene polymorphism that may provide a survival advantage for heterozygous carriers with severe sepsis. We sought to confirm that carriers of this prothrombotic factor V Leiden mutation do not have an increased risk of developing severe sepsis and that carriers with severe sepsis derive similar treatment benefit from recombinant human activated protein C (drotrecogin alfa [activated]) as non-factor V Leiden carriers. | lld:pubmed |
| pubmed-article:15118525 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15118525 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15118525 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:15118525 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15118525 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15118525 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15118525 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15118525 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15118525 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15118525 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15118525 | pubmed:month | May | lld:pubmed |
| pubmed-article:15118525 | pubmed:issn | 0090-3493 | lld:pubmed |
| pubmed-article:15118525 | pubmed:author | pubmed-author:NelsonDavid... | lld:pubmed |
| pubmed-article:15118525 | pubmed:author | pubmed-author:YanS BettySB | lld:pubmed |
| pubmed-article:15118525 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15118525 | pubmed:volume | 32 | lld:pubmed |
| pubmed-article:15118525 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15118525 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15118525 | pubmed:pagination | S239-46 | lld:pubmed |
| pubmed-article:15118525 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15118525 | pubmed:meshHeading | pubmed-meshheading:15118525... | lld:pubmed |
| pubmed-article:15118525 | pubmed:meshHeading | pubmed-meshheading:15118525... | lld:pubmed |
| pubmed-article:15118525 | pubmed:meshHeading | pubmed-meshheading:15118525... | lld:pubmed |
| pubmed-article:15118525 | pubmed:meshHeading | pubmed-meshheading:15118525... | lld:pubmed |
| pubmed-article:15118525 | pubmed:meshHeading | pubmed-meshheading:15118525... | lld:pubmed |
| pubmed-article:15118525 | pubmed:meshHeading | pubmed-meshheading:15118525... | lld:pubmed |
| pubmed-article:15118525 | pubmed:meshHeading | pubmed-meshheading:15118525... | lld:pubmed |
| pubmed-article:15118525 | pubmed:meshHeading | pubmed-meshheading:15118525... | lld:pubmed |
| pubmed-article:15118525 | pubmed:meshHeading | pubmed-meshheading:15118525... | lld:pubmed |
| pubmed-article:15118525 | pubmed:meshHeading | pubmed-meshheading:15118525... | lld:pubmed |
| pubmed-article:15118525 | pubmed:meshHeading | pubmed-meshheading:15118525... | lld:pubmed |
| pubmed-article:15118525 | pubmed:meshHeading | pubmed-meshheading:15118525... | lld:pubmed |
| pubmed-article:15118525 | pubmed:meshHeading | pubmed-meshheading:15118525... | lld:pubmed |
| pubmed-article:15118525 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15118525 | pubmed:articleTitle | Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. | lld:pubmed |
| pubmed-article:15118525 | pubmed:affiliation | Lilly Research Laboratories, Indianapolis, IN, USA. | lld:pubmed |
| pubmed-article:15118525 | pubmed:publicationType | Journal Article | lld:pubmed |
| entrez-gene:2153 | entrezgene:pubmed | pubmed-article:15118525 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:15118525 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15118525 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15118525 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15118525 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15118525 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15118525 | lld:pubmed |
